247 related articles for article (PubMed ID: 27784788)
1. Altering the Proteoglycan State of Transforming Growth Factor β Type III Receptor (TβRIII)/Betaglycan Modulates Canonical Wnt/β-Catenin Signaling.
Jenkins LM; Singh P; Varadaraj A; Lee NY; Shah S; Flores HV; O'Connell K; Mythreye K
J Biol Chem; 2016 Dec; 291(49):25716-25728. PubMed ID: 27784788
[TBL] [Abstract][Full Text] [Related]
2. Glycosaminoglycan modifications of betaglycan regulate ectodomain shedding to fine-tune TGF-β signaling responses in ovarian cancer.
Choi AS; Jenkins-Lane LM; Barton W; Kumari A; Lancaster C; Raulerson C; Ji H; Altomare D; Starr MD; Whitaker R; Phaeton R; Arend R; Shtutman M; Nixon AB; Hempel N; Lee NY; Mythreye K
Cell Commun Signal; 2024 Feb; 22(1):128. PubMed ID: 38360757
[TBL] [Abstract][Full Text] [Related]
3. Dually modified transmembrane proteoglycans in development and disease.
Jenkins LM; Horst B; Lancaster CL; Mythreye K
Cytokine Growth Factor Rev; 2018 Feb; 39():124-136. PubMed ID: 29291930
[TBL] [Abstract][Full Text] [Related]
4. Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor.
Kirkbride KC; Townsend TA; Bruinsma MW; Barnett JV; Blobe GC
J Biol Chem; 2008 Mar; 283(12):7628-37. PubMed ID: 18184661
[TBL] [Abstract][Full Text] [Related]
5. Binding of two growth factor families to separate domains of the proteoglycan betaglycan.
Andres JL; DeFalcis D; Noda M; Massagué J
J Biol Chem; 1992 Mar; 267(9):5927-30. PubMed ID: 1556106
[TBL] [Abstract][Full Text] [Related]
6. The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2.
You HJ; How T; Blobe GC
Carcinogenesis; 2009 Aug; 30(8):1281-7. PubMed ID: 19325136
[TBL] [Abstract][Full Text] [Related]
7. Amino acid determinants that drive heparan sulfate assembly in a proteoglycan.
Zhang L; Esko JD
J Biol Chem; 1994 Jul; 269(30):19295-9. PubMed ID: 8034692
[TBL] [Abstract][Full Text] [Related]
8. Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion.
Elderbroom JL; Huang JJ; Gatza CE; Chen J; How T; Starr M; Nixon AB; Blobe GC
Mol Biol Cell; 2014 Aug; 25(16):2320-32. PubMed ID: 24966170
[TBL] [Abstract][Full Text] [Related]
9. Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression.
Gordon KJ; Dong M; Chislock EM; Fields TA; Blobe GC
Carcinogenesis; 2008 Feb; 29(2):252-62. PubMed ID: 17999987
[TBL] [Abstract][Full Text] [Related]
10. Heparan sulfate modifications of betaglycan promote TIMP3-dependent ectodomain shedding to fine-tune TGF-β signaling.
Choi AS; Jenkins-Lane LM; Barton W; Kumari A; Lancaster C; Raulerson C; Ji H; Altomare D; Starr MD; Whitaker R; Phaeton R; Arend R; Shtutman M; Nixon AB; Hempel N; Lee NY; Mythreye K
bioRxiv; 2023 Aug; ():. PubMed ID: 37693479
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of type III TGF-β receptor aggravates lung fibrotic process.
Ahn JY; Park S; Yun YS; Song JY
Biomed Pharmacother; 2010 Sep; 64(7):472-6. PubMed ID: 20359848
[TBL] [Abstract][Full Text] [Related]
12. Betaglycan inhibits TGF-beta signaling by preventing type I-type II receptor complex formation. Glycosaminoglycan modifications alter betaglycan function.
Eickelberg O; Centrella M; Reiss M; Kashgarian M; Wells RG
J Biol Chem; 2002 Jan; 277(1):823-9. PubMed ID: 11668175
[TBL] [Abstract][Full Text] [Related]
13. Roles for the type III TGF-beta receptor in human cancer.
Gatza CE; Oh SY; Blobe GC
Cell Signal; 2010 Aug; 22(8):1163-74. PubMed ID: 20153821
[TBL] [Abstract][Full Text] [Related]
14. Inhibition by chondroitin sulfate E can specify functional Wnt/β-catenin signaling thresholds in NIH3T3 fibroblasts.
Willis CM; Klüppel M
J Biol Chem; 2012 Oct; 287(44):37042-56. PubMed ID: 22915582
[TBL] [Abstract][Full Text] [Related]
15. The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells.
Lambert KE; Huang H; Mythreye K; Blobe GC
Mol Biol Cell; 2011 May; 22(9):1463-72. PubMed ID: 21411633
[TBL] [Abstract][Full Text] [Related]
16. A tumor-promoting role for soluble TβRIII in glioblastoma.
Burghardt I; Schroeder JJ; Weiss T; Gramatzki D; Weller M
Mol Cell Biochem; 2021 Aug; 476(8):2963-2973. PubMed ID: 33772427
[TBL] [Abstract][Full Text] [Related]
17. The transforming growth factor-beta type III receptor mediates distinct subcellular trafficking and downstream signaling of activin-like kinase (ALK)3 and ALK6 receptors.
Lee NY; Kirkbride KC; Sheu RD; Blobe GC
Mol Biol Cell; 2009 Oct; 20(20):4362-70. PubMed ID: 19726563
[TBL] [Abstract][Full Text] [Related]
18. Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth.
Gatza CE; Holtzhausen A; Kirkbride KC; Morton A; Gatza ML; Datto MB; Blobe GC
Neoplasia; 2011 Aug; 13(8):758-70. PubMed ID: 21847367
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III.
Yan Z; Deng X; Friedman E
J Biol Chem; 2001 Jan; 276(2):1555-63. PubMed ID: 11029459
[TBL] [Abstract][Full Text] [Related]
20. Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta.
Hempel N; How T; Cooper SJ; Green TR; Dong M; Copland JA; Wood CG; Blobe GC
Carcinogenesis; 2008 May; 29(5):905-12. PubMed ID: 18299279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
